July 7, 2026 - 00:41

DXC Technology continues to draw positive attention from analysts, with the stock maintaining a "Buy" rating based on its strategic focus on artificial intelligence and operational efficiency. The company's long-term financial targets, set for fiscal year 2029, appear achievable according to recent assessments.
A key driver for this optimism is DXC's OASIS platform, which leverages AI to modernize legacy IT systems for clients. This initiative is expected to accelerate revenue growth as businesses increasingly seek digital transformation solutions. Alongside this, DXC has been aggressively pursuing cost optimization measures, which are projected to improve profit margins over the next several years.
The company's valuation also supports the bullish outlook. Current stock prices do not fully reflect the potential earnings growth from these initiatives. With a clear roadmap for margin expansion and a growing foothold in AI-driven services, DXC is positioned to deliver steady returns. While near-term market volatility remains a factor, the fundamental strategy and achievable targets provide a solid foundation for long-term investors. The focus on disciplined execution and emerging technology adoption suggests the company can meet its fiscal 2029 goals without major disruption.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...